Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) EBT (2019 - 2025)

Avidity Biosciences' EBT history spans 7 years, with the latest figure at -$236.6 million for Q4 2025.

  • For Q4 2025, EBT fell 130.95% year-over-year to -$236.6 million; the TTM value through Dec 2025 reached -$682.7 million, down 111.98%, while the annual FY2025 figure was -$682.7 million, 111.98% down from the prior year.
  • EBT reached -$236.6 million in Q4 2025 per RNA's latest filing, down from -$174.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$23.8 million in Q1 2021 to a low of -$236.6 million in Q4 2025.
  • Average EBT over 5 years is -$75.4 million, with a median of -$52.2 million recorded in 2023.
  • Peak YoY movement for EBT: crashed 291.8% in 2021, then dropped 2.57% in 2023.
  • A 5-year view of EBT shows it stood at -$38.5 million in 2021, then tumbled by 31.07% to -$50.5 million in 2022, then fell by 19.59% to -$60.3 million in 2023, then tumbled by 69.81% to -$102.5 million in 2024, then tumbled by 130.95% to -$236.6 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's EBT are -$236.6 million (Q4 2025), -$174.1 million (Q3 2025), and -$156.7 million (Q2 2025).